51–60 of 85 posts
Satisfying, to say the least. Unlike a $5 million slap on the wrist.
But how many fractions of a percent of their revenue does this really represent?
Earlier quoted context omitted.
> And if the law doesn't allow it, but the regulators never drop the hammer, don't expect people not to do it. I'm not saying it isn't fraud. I'm saying that its par for the course when regulators rarely take action. Mylan got greedy and got slapped. Regulatory bodies in the US are woefully underfunded and this sort of thing is the result. Blame congress.
64% of murders currently result in an conviction. At what percentage would it no longer be the perpetrators responsibility for the crime and instead be the fault of the lawmakers lack of ability to bring him to justice?
So from an accounting perspective is the Government just one more highly paid executive?
Earlier quoted context omitted.
But how many fractions of a percent of their revenue does this really represent?
Would you rather they were crushed, and all the employees that had nothing to do with this (of which there are tens of thousands) were harshly affected?
So if $1.3B was spent and the rebate was short by 10% then Mylan should have paid $130M more. That indicates somewhere around $365M is essentially punitive. (Or, if $1.3B was net of the 13% already paid, the gross was $1.49B, the underpayment was $149M and the punitive cost $316M)
For people using the word "fraud." Fraud requires some misrepresentation of a material fact. Nobody at CMS was unaware of what an Epipen was, depending on Mylan's representations about what was in there. This is a fight over whether Mylan should have checked Box A or Box B. There is a reasonable case to be made for both sides. After all, the drug in an Epipen (epinephrine) is generic. For people talking about throwin…
I'd like to see the execs barred from country clubs, and a 2yr ban on playing golf.
That would just give them most time at the office causing more of this!
And this will solve absolutely nothing. Change the system if you want real change. Allow competitors on the market to diminish Mylan's stranglehold on it.
Earlier quoted context omitted.
Adrenaclick and generic versions of it. It's not a direct substitute, it can't be dispensed to fill an Epipen prescription, but it is the same drug, the same dose, and for the same purpose (emergency administration of epinephrine by lightly trained persons). http://www.goodrx.com/adrenaclick
If it is the same drug, dose, and usage I must profess a bit of confusion as to what could possibly be preventing it from being a direct substitute.
https://www.epipen.com/about-epipen/how-to-use-epipen
http://adrenaclick.com/how_to_use_adrenaclick_epinephrine_in...
I think there is a legitimate concern about the usage being different, but I'm not sure it should prevent it from being substituted.
Earlier quoted context omitted.
It's not a monopoly. There have been and continue to be other epinephrine auto-injectors from competitors.
Have been, but what else is on the market right now in the US? Why is that? Its not for lack of demand.